THRIVENT FINANCIAL FOR LUTHERANS - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.

Quarter-by-quarter ownership
THRIVENT FINANCIAL FOR LUTHERANS ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$76,944
+2.6%
2,014,233
-3.1%
0.18%
+7.0%
Q2 2023$74,984
+82.4%
2,078,838
+93.1%
0.17%
+71.0%
Q1 2023$41,119
-21.4%
1,076,716
+17.1%
0.10%
-26.5%
Q4 2022$52,327
-99.9%
919,636
-30.2%
0.14%
-4.9%
Q3 2022$52,104,000
-10.7%
1,317,732
-0.6%
0.14%
-7.7%
Q2 2022$58,346,000
-0.3%
1,326,058
-9.6%
0.16%
+36.0%
Q1 2022$58,502,000
+35.1%
1,466,968
+36.2%
0.11%
+35.7%
Q4 2021$43,300,000
+41.3%
1,076,833
+43.0%
0.08%
+35.5%
Q3 2021$30,642,000
-12.1%
753,248
-1.9%
0.06%
-12.7%
Q2 2021$34,862,000
+13.9%
767,708
+4.6%
0.07%
+6.0%
Q1 2021$30,599,000
-42.5%
733,976
-41.1%
0.07%
-45.5%
Q4 2020$53,243,000
+70.3%
1,246,615
+4.8%
0.12%
+46.4%
Q3 2020$31,268,000
-1.1%
1,189,801
+0.9%
0.08%
-11.6%
Q2 2020$31,619,000
+49.7%
1,179,378
+0.4%
0.10%
+25.0%
Q1 2020$21,124,000
+1.2%
1,174,208
-0.3%
0.08%
+28.8%
Q4 2019$20,876,000
-65.2%
1,177,440
-69.5%
0.06%
-68.3%
Q3 2019$59,957,000
-7.8%
3,865,719
+2.1%
0.19%
-6.1%
Q2 2019$65,038,000
+10.1%
3,785,665
+3.2%
0.20%
+6.5%
Q1 2019$59,084,000
+13.4%
3,669,830
+3.0%
0.19%
-1.1%
Q4 2018$52,120,000
-8.5%
3,562,505
+13.6%
0.19%
+5.0%
Q3 2018$56,976,000
+45.8%
3,135,730
+35.4%
0.18%
+40.9%
Q2 2018$39,073,0002,316,1370.13%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders